A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
Evanthia Galanis(The University of Texas at San Antonio Health Science Center), David Schiff(University of Virginia Medical Center)
Cited by 70
Related Papers
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
|Journal of Clinical Oncology|2021|775
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
|Journal of Clinical Oncology|2005|695
Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
|Journal of Clinical Investigation|2021|61